Search

Displaying results 3451 - 3460 of 7018 in total
  1. Drug

    Pipamperone

    go.drugbank.com/drugs/DB09286
    Investigational

    drugs at this time, had significant anti-tryptamine activity. … Interestingly, when [risperidone] was created, Janssen suggested it was a more potent version of pipamperone.

  2. Drug

    Tunicamycin

    go.drugbank.com/drugs/DB13172
    Experimental

    Tunicamycin blocks N-linked glycosylation (N-glycans) resulting in cell cycle arrest at the G1 phase in human cells. It is used as an experimental tool to induce unfolded protein response. … Tunicamycin is a mixture of homologous nucleoside antibiotics that inhibits the UDP-HexNAc: polyprenol-P HexNAc-1-P family of enzymes.

  3. Drug

    1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol))

    go.drugbank.com/drugs/DB11331
    ApprovedWithdrawn

    Palmitoyloleoyl-phosphatidylglycerol was a component of Surfaxin, discontinued in 2017, which acted as a surfactant [FDA Label].

  4. Drug

    N-[(2S,4S,6R)-2-(dihydroxymethyl)-4-hydroxy-3,3-dimethyl-7-oxo-4lambda~4~-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenylacetamide

    go.drugbank.com/drugs/DB08559
    Experimental

    from the sulfur atom at position 1]. … These are organic compounds containing the penicillin core structure, which is structurally characterized by a penam ring bearing two methyl groups at position 2, and an amide group at position 6 [starting

  5. Drug

    LetibotulinumtoxinA

    go.drugbank.com/drugs/DB16820
    Approved

    [L42330] It is a 900 kDa multimeric complex comprising a 150 kDa toxin, a 130 kDa non-toxic non-haemagglutinating protein, and various other haemagglutinins. … [A249920] LetibotulinumtoxinA is a type A botulinum neurotoxin produced from fermentation of _Clostridium botulinum_ strain CBFC26.

    Categories: Botulinum Toxins, Type ASynonyms: BoNT/A-DS
  6. Drug

    Motixafortide

    go.drugbank.com/drugs/DB14939
    ApprovedInvestigational

    [L48136] Similar in mechanism to the previously approved [plerixafor], motixafortide is an inhibitor of C-X-C Motif Chemokine Receptor 4 (CXCR4), a protein that helps to anchor stem cells to bone marrow … Motixafortide is a cyclic peptide hematopoietic stem cell mobilizer used to improve stem cell collection prior to autologous transplantation.

  7. Drug

    Almonertinib

    go.drugbank.com/drugs/DB16640
    ApprovedInvestigational

    [A231859, A231864, A231869] Unlike other third-generation EGFR TKIs, almonertinib is a pyrimidine-based drug that forms a covalent bond to the binding site of the EGFR tyrosine kinase domain. … Almonertinib is a third-generation EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing and T790M resistance mutations.

  8. Drug

    Inetetamab

    go.drugbank.com/drugs/DB17457
    Investigational

    Inetetamab is a trastuzumab analog. It differs from trastuzumab by a two amino acid variation in its Fc domain (allotype variation), and possesses an exact F(ab’)2 of trastuzumab.

  9. Drug

    Irofulven

    go.drugbank.com/drugs/DB05786
    Investigational

    A novel anti-cancer compound synthesized by scientists at the University of California, San Diego more than a decade ago from toxins of the poisonous jack-o-lantern mushroom, has been granted “fast track … Phase III clinical trials involving the drug have been underway since early 2001 at sites in the U.S. and Europe.

  10. Drug

    Norclozapine

    go.drugbank.com/drugs/DB05766
    Investigational

    ACP-104, or N-desmethylclozapine, is the major metabolite of clozapine, and is being developed by ACADIA as a novel, stand-alone therapy for schizophrenia. … It combines an atypical antipsychotic efficacy profile with the added potential benefit of enhanced cognition, thereby addressing one of the major challenges in treating schizophrenia today.